SEARCH:   Advanced

Blood, 15 June 2004, Vol. 103, No. 12, pp. 4613-4615. Prepublished online as a Blood First Edition Paper on February 26, 2004; DOI 10.1182/blood-2003-11-3903. This Article Full Text (PDF) All Versions of this Article: 2003-11-3903v1 103/12/4613    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Savage, P. Articles by Stauss, H. J Search for Related Content PubMed PubMed Citation Articles by Savage, P. Articles by Stauss, H. J Related Collections Related Article in Blood Online Social Bookmarking                   What's this? Submitted November 13, 2003 Accepted February 4, 2004 Use of B-cell bound HLA-A2 class I monomers to generate high avidity, allo-restricted CTL against the leukemia-associated protein Wilms tumor antigen 1 Philip Savage, Liquan Gao, Kevin Vento, Pam Cowburn, Stephen Man, Neil Steven, Graham Ogg, Andrew McMichael, Agamemnon Epenetos, Els Goulmy, and Hans J Stauss* Alexis Biotechnology, London, United Kingdom; Velindre Hospital, Cancer Research Wales, Cardiff, United Kingdom Immunology/Tumor Immunology, Imperial College, London, United Kingdom Velindre Hospital, Cancer Research Wales, Cardiff, United Kingdom Section of Infection and Immunity, University of Wales College of Medicine, Cardiff, United Kingdom Division of Cancer Studies, University of Birmingham, Birmingham, United Kingdom Human Immunology Unit, Institute of Molecular Medicine, Oxford, United Kingdom Alexis Biotechnology, London, United Kingdom; Dept of Medical Oncology, St Bartholomews Hospital, London, United Kingdom Department of Immunohematology and Blood Transfusion, Leiden University Medical Centre, Leiden, The Netherlands * Corresponding author; email: h.stauss{at}imperial.ac.uk. Recent studies have detected WT1-specific CTL in AML and CML patients and demonstrated that most of these CTL were low avidity. Although HLA-mismatched donors can mount high avidity CTL against HLA-A2-presented peptides of WT1, a dominant anti-allo immune response usually obscures detection of peptide-specific CTL. Here we explored the feasibility of using recombinant HLA-A2 monomers containing single peptide epitopes as immunogens to generate peptide-specific CTL from allogeneic donors. We demonstrate that the coating of HLA-A2-negative B lymphocytes with A2/peptide monomers provides a strong stimulus for autologous peptide-specific CTL. After 3-5 rounds of stimulation a population of CD8+ T cells binding A2/peptide tetramers is easily detectable by FACS analysis. Furthermore, sorted A2/WT1 tetramer-positive CTL display strong cytotoxic activity against leukemia cells expressing WT1 endogenously but not against WT1-negative human tumor cells. Thus, HLA/peptide monomers may be useful to isolate peptide-specific donor lymphocytes for treatment of leukemia patients after HLA-mismatched transplantation. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Generating CTL by HLA transplant Moniek A. de Witte and Ton N. M. Schumacher Blood 2004 103: 4381-4382. [Full Text] [PDF] This article has been cited by other articles: S. Wilde, D. Sommermeyer, B. Frankenberger, M. Schiemann, S. Milosevic, S. Spranger, H. Pohla, W. Uckert, D. H. Busch, and D. J. Schendel Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity Blood, September 3, 2009; 114(10): 2131 - 2139. [Abstract] [Full Text] [PDF] X. Weng, S. Lu, M. Zhong, Z. Liang, G. Shen, J. Chen, and X. Wu Allo-restricted CTLs generated by coculturing of PBLs and autologous monocytes loaded with allogeneic peptide/HLA/IgG1-Fc fusion protein J. Leukoc. Biol., March 1, 2009; 85(3): 574 - 581. [Abstract] [Full Text] [PDF] C. Chaise, S. L. Buchan, J. Rice, J. Marquet, H. Rouard, M. Kuentz, G. E. Vittes, V. Molinier-Frenkel, J.-P. Farcet, H. J. Stauss, et al. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance Blood, October 1, 2008; 112(7): 2956 - 2964. [Abstract] [Full Text] [PDF] D. J. Powell Jr., M. E. Dudley, K. A. Hogan, J. R. Wunderlich, and S. A. Rosenberg Adoptive Transfer of Vaccine-Induced Peripheral Blood Mononuclear Cells to Patients with Metastatic Melanoma following Lymphodepletion J. Immunol., November 1, 2006; 177(9): 6527 - 6539. [Abstract] [Full Text] [PDF] M. J. Pittet, A. Gati, F.-A. Le Gal, G. Bioley, P. Guillaume, M. de Smedt, J. Plum, D. E. Speiser, J.-C. Cerottini, P.-Y. Dietrich, et al. Ex Vivo Characterization of Allo-MHC-Restricted T Cells Specific for a Single MHC-Peptide Complex J. Immunol., February 15, 2006; 176(4): 2330 - 2336. [Abstract] [Full Text] [PDF] A. M. E. Whitelegg, L. E. M. Oosten, S. Jordan, M. Kester, A. G. S. van Halteren, J. A. Madrigal, E. Goulmy, and L. D. Barber Investigation of Peptide Involvement in T Cell Allorecognition Using Recombinant HLA Class I Multimers J. Immunol., August 1, 2005; 175(3): 1706 - 1714. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020